leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 16:27:25 - browse：5297

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: BridgeBio, Akero, and human embryo models

WSS

Streamlined flu vaccines recommended by FDA advisory panel

Longer MASH drug regimen improved liver, Akero study finds

For AI in health care standards, federal regulators join with industry group

What health policies could hitch a ride on a spending bill?

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

For AI in health care standards, federal regulators join with industry group

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

First over

Peter Hotez and the public health issue of online harassment

Study suggests Covid rebound is far more common with Paxlovid than without

23andMe had bad news about my health. I wish a person had delivered it

State of the Union pitch: Bigger Medicare drug price negotiations

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: BridgeBio, Akero, and human embryo models

Medicare details structure of new drug price negotiation program

For AI in health care standards, federal regulators join with industry group

Wikipedia

FDA reorg will put new emphasis on investigations, sources say

Medicare drug price negotiation hearing pits pharma v Biden admin

Families look for replacement for GSK asthma drug Flovent

Medicare’s new pay boost for primary care is angering specialists

Longer MASH drug regimen improved liver, Akero study finds

CVS, Rite Aid closures threaten to worsen pharmacy deserts

explore

leisure time

explore

entertainment